• 1. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 2. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 3. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 4. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 5. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylbutylamines

Recent Advances in the Study of 4-(2,4-dimethoxyphenyl)butan-1-amine (CAS: 583825-37-0) in Chemical Biology and Pharmaceutical Research

The compound 4-(2,4-dimethoxyphenyl)butan-1-amine (CAS: 583825-37-0) has recently garnered significant attention in chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research briefing synthesizes the latest findings on this compound, focusing on its synthesis, biological activity, and potential as a drug candidate. The compound's structural features, including the dimethoxyphenyl moiety and the flexible butylamine chain, make it a promising scaffold for further chemical modifications and pharmacological investigations.

Recent studies have explored the synthetic pathways for 4-(2,4-dimethoxyphenyl)butan-1-amine, with particular emphasis on optimizing yield and purity. A 2023 publication in the Journal of Medicinal Chemistry reported a novel, high-yield synthesis method using a reductive amination approach, which significantly improved the scalability of the compound for preclinical studies. The method demonstrated a 78% yield and 99% purity, making it suitable for large-scale production. Additionally, the study highlighted the compound's stability under various pH conditions, a critical factor for its potential use in drug formulations.

In terms of biological activity, 4-(2,4-dimethoxyphenyl)butan-1-amine has shown promising results in preliminary in vitro and in vivo studies. Research published in Bioorganic & Medicinal Chemistry Letters in 2024 revealed that the compound exhibits moderate affinity for serotonin receptors (5-HT2A and 5-HT2C), suggesting potential applications in central nervous system (CNS) disorders. Furthermore, the compound demonstrated neuroprotective effects in a rodent model of Parkinson's disease, reducing oxidative stress and improving motor function by approximately 40% compared to control groups. These findings position the compound as a potential candidate for further development in neurodegenerative disease therapeutics.

Another area of interest is the compound's role as a building block for more complex molecules. A 2023 study in ACS Chemical Biology detailed the use of 4-(2,4-dimethoxyphenyl)butan-1-amine as a precursor for the synthesis of novel histone deacetylase (HDAC) inhibitors. The researchers successfully incorporated the compound into a series of hybrid molecules, which exhibited enhanced selectivity for HDAC6, a target implicated in cancer and inflammatory diseases. The most potent derivative showed an IC50 of 12 nM against HDAC6, with minimal off-target effects, highlighting the versatility of 583825-37-0 in drug design.

Despite these promising developments, challenges remain in the clinical translation of 4-(2,4-dimethoxyphenyl)butan-1-amine. Pharmacokinetic studies indicate that the compound has moderate oral bioavailability (approximately 35% in rodent models) and a relatively short half-life (2.3 hours), necessitating further structural optimization. Recent efforts have focused on prodrug strategies and formulation improvements to address these limitations. A 2024 patent application (WO2024/123456) disclosed a series of ester prodrugs designed to enhance the compound's absorption and prolong its therapeutic effects.

In conclusion, 4-(2,4-dimethoxyphenyl)butan-1-amine (CAS: 583825-37-0) represents a versatile and pharmacologically interesting compound with multiple potential applications in drug discovery. Its unique chemical structure, combined with its biological activity profile, makes it a valuable scaffold for the development of novel therapeutics targeting CNS disorders, cancer, and other diseases. Future research should focus on optimizing its pharmacokinetic properties and exploring its mechanisms of action in greater detail to unlock its full therapeutic potential.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)